Germany · Delayed Price · Currency is EUR Waverley Pharma Statistics
Total Valuation
Waverley Pharma has a market cap or net worth of EUR 497,749. The enterprise value is 2.44 million.
| Market Cap | 497,749 |
| Enterprise Value | 2.44M |
Important Dates
The last earnings date was Thursday, November 27, 2025.
| Earnings Date | Nov 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 54.00M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 74.90% |
| Owned by Institutions (%) | n/a |
| Float | 13.55M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.54 |
| PB Ratio | -0.34 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.85 |
| EV / Sales | 2.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11
| Current Ratio | 0.11 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.63 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -12.30% |
| Return on Invested Capital (ROIC) | -20.83% |
| Return on Capital Employed (ROCE) | 13.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.99 |
| Inventory Turnover | 4.24 |
Taxes
In the past 12 months, Waverley Pharma has paid 998 in taxes.
| Income Tax | 998 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 22.44 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Waverley Pharma had revenue of EUR 921,238 and -224,633 in losses. Loss per share was -0.00.
| Revenue | 921,238 |
| Gross Profit | 363,687 |
| Operating Income | -184,012 |
| Pretax Income | -223,635 |
| Net Income | -224,633 |
| EBITDA | -137,424 |
| EBIT | -184,012 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 41,384 in cash and 1.97 million in debt, giving a net cash position of -1.93 million.
| Cash & Cash Equivalents | 41,384 |
| Total Debt | 1.97M |
| Net Cash | -1.93M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.45M |
| Book Value Per Share | -0.03 |
| Working Capital | -1.87M |
Cash Flow
| Operating Cash Flow | -283,382 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 39.48%, with operating and profit margins of -19.97% and -24.38%.
| Gross Margin | 39.48% |
| Operating Margin | -19.97% |
| Pretax Margin | -24.28% |
| Profit Margin | -24.38% |
| EBITDA Margin | -14.92% |
| EBIT Margin | -19.97% |
| FCF Margin | n/a |
Dividends & Yields
Waverley Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -45.13% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Waverley Pharma has an Altman Z-Score of -14.03 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.03 |
| Piotroski F-Score | 2 |